Sign In
Buy NTLA
$12.02
+0.0800 (+0.670%)
At Close: Aug 10, 2026
Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought
10:47am, Wednesday, 01'st Oct 2025
Cathie Wood is having a good year. The Ark Invest founder, CEO, and ace stock picker isn't back to her peak 2020 form when many of her exchange-traded funds (ETFs) more than doubled in value.
Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
01:57pm, Thursday, 25'th Sep 2025
Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary
CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis
02:31pm, Friday, 19'th Sep 2025
News shared this week that Intellia Therapeutics, Inc.'s pivotal study of candidate lonvo-z is fully enrolled has been greeted warmly by the market, with good reason. NTLA stock remains a compelling B
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
01:26pm, Friday, 19'th Sep 2025
Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.
Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength?
10:21am, Friday, 19'th Sep 2025
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
2 More Stocks With 1,000% Upside
12:00pm, Sunday, 14'th Sep 2025
Tom Yeung here with your Sunday Digest . Almost every multimillionaire investor I know has their version of “The One” – a single investment that built much of their wealth.
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%
03:45am, Thursday, 11'th Sep 2025
Cathie Wood is known for seizing opportunities. The founder of Ark Invest doesn't worry when one of the stocks she's invested in drops, and instead, she looks at the movement as a chance to increase h
Why big players are pouring millions in THIS biotech stock
08:43am, Monday, 01'st Sep 2025
Intellia Therapeutics (NASDAQ: NTLA) has been getting a lot of buzz lately among investors who follow the biotech space. The company uses CRISPR gene editing technology to develop treatments, and whil
Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)
12:24pm, Friday, 15'th Aug 2025
Intellia Therapeutics, Inc.'s lead gene-editing therapies, Lonvo-z and Nex-z, show best-in-class potential with 'one and done' treatment and strong early efficacy and safety data. Recent safety concer
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
12:21pm, Friday, 08'th Aug 2025
NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.
Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript
08:17pm, Thursday, 07'th Aug 2025
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Brittany Chaves - Corporate Participant David Lebwohl - Executive VP & Chief
Intellia (NTLA) Q2 Revenue Jumps 106%
11:23am, Thursday, 07'th Aug 2025
Intellia (NTLA) Q2 Revenue Jumps 106%
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates
09:41am, Thursday, 07'th Aug 2025
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $1.31 per share a year ago.
